Scholar Rock Holding Corp

Scholar Rock is a biopharmaceutical company focused on discovering and developing therapies for spinal muscular atrophy and other rare neuromuscular conditions. Using a proprietary platform that targets latent growth factor precursors within tissue microenvironments, the company builds an anti-myostatin pipeline. Its lead product candidates include apitegromab, an investigational monoclonal antibody designed to inhibit myostatin activation in muscle, and SRK-439. The company develops treatments intended for pediatric and adult patients suffering from debilitating neuromuscular disorders.

The company operates with clinical development activities spanning the United States and Europe, supported by a customer-facing workforce of approximately fifty professionals in the United States and commercial readiness initiatives beginning in Germany. It aims to serve patient populations across a platform covering more than fifty countries globally. The provided text mentions scientific roots at Harvard Medical School and Boston Children’s Hospital, but it does not state the city or location of the company's corporate headquarters.

Summary of the business section of Scholar Rock's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 24, 2026, we had 289 full-time employees, of which 137 employees are engaged in research and development activities and 152 are engaged in general and administrative activities.”